What is SCP Vitalife's investment focus?

SCP Vitalife is a venture capital firm that focuses on life sciences investments in Israel and the United States, targeting early to mid-stage companies with exceptional technologies.

Which sectors does SCP Vitalife primarily invest in?

SCP Vitalife primarily invests in the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.

Can you name a notable exit for SCP Vitalife in recent years?

In September 2018, SCP Vitalife saw an exit with MST - Medical Surgery Technologies, which was acquired by Asensus for $34 million.

What is SCP Vitalife's geographic investment strategy?

SCP Vitalife allocates over half of its investment capital to Israeli companies or companies with significant R&D and operational ties to Israel, with the remainder going to companies based in the United States.

Who is a key team member at SCP Vitalife?

Jeff Dykan is a Managing Partner at SCP Vitalife.

What is one of SCP Vitalife's portfolio companies that went public?

SCP Vitalife has a portfolio company, Lifeward, which went public on NASDAQ in September 2014 with a valuation of $136 million.

What is another public exit for SCP Vitalife?

Regentis Biomaterials, a portfolio company of SCP Vitalife, is expected to have a public offering on NASDAQ in September 2025.

SCP Vitalife

Venture Capital Active Ra'anana, Israel Est. 2002

Visit website ↗

Last updated 2026-06-18

Portfolio

in our dataset

Rounds participated

Rounds led

Rounds' value

$110.4M

total disclosed, rounds participated

Stages

B Round, A Round, F Round, C Round, D Round, E Round, Seed, Pre-Seed, G Round

About

SCP Vitalife is a venture capital firm focused on life sciences investments in Israel and the United States. The firm seeks to invest in early to mid-stage life sciences companies with exceptional technologies or other proprietary advantages. SCP Vitalife allocates over half of its investment capital to investments in Israeli companies or companies that have significant R&D and operational ties to Israel. The remainder of the fund's investment capital is allocated to companies based in the United States. The fund's target initial investment size is between $3 million and $7 million, with a typical total investment of $7 million to $15 million over the lifespan of the investment.

Portfolio · 9

Regentis Biomaterials

Implantable Hydrogel Platform for Tissue Regeneration

3 rounds $32.5M committed Latest: 2016-02

MST - Medical Surgery Technologies

Image-based Software for Robotic Surgery

1 round $12.5M committed Latest: 2015-07

Sensible Medical Innovations

Noninvasive Lung Fluid Monitoring and Management

1 round $20.0M committed Latest: 2013-11

Lifeward

Battery-powered Walking System

2 rounds $10.1M committed Latest: 2011-07

Trig Medical

Ultrasound Tracking and Monitoring Solutions for Childbirth

1 round $4.1M committed Latest: 2009-08

novoGi

GI Disease Management

1 round $18.5M committed Latest: 2009-08

POCARED Diagnostics

Automated, Reagent-free Microorganism Detection

1 round $10.7M committed Latest: 2007-06

Beta-O2 Technologies

Implantable Bioreactor for Treating Type 1 Diabetes

1 round $2.0M committed Latest: 2004-03

GeneGrafts

Cell Therapy for Modulating Excitable Tissues

1 round Latest: 2003-12

Investment activity

3 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences9

Q&A

What is SCP Vitalife's investment focus?: SCP Vitalife is a venture capital firm that focuses on life sciences investments in Israel and the United States, targeting early to mid-stage companies with exceptional technologies.
What is SCP Vitalife's typical initial investment size?: SCP Vitalife's target initial investment size is between $3 million and $7 million, with a typical total investment of $7 million to $15 million over the lifespan of an investment.
Which sectors does SCP Vitalife primarily invest in?: SCP Vitalife primarily invests in the Health Tech & Life Sciences sector, with all of its portfolio companies and exits concentrated in this area.
Can you name a notable exit for SCP Vitalife in recent years?: In September 2018, SCP Vitalife saw an exit with MST - Medical Surgery Technologies, which was acquired by Asensus for $34 million.
What is SCP Vitalife's geographic investment strategy?: SCP Vitalife allocates over half of its investment capital to Israeli companies or companies with significant R&D and operational ties to Israel, with the remainder going to companies based in the United States.
Who is a key team member at SCP Vitalife?: Jeff Dykan is a Managing Partner at SCP Vitalife.
What is one of SCP Vitalife's portfolio companies that went public?: SCP Vitalife has a portfolio company, Lifeward, which went public on NASDAQ in September 2014 with a valuation of $136 million.
What is another public exit for SCP Vitalife?: Regentis Biomaterials, a portfolio company of SCP Vitalife, is expected to have a public offering on NASDAQ in September 2025.

Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Website	scpvitalife.com/

Identifiers & details

Founded	2002

Radar intelligence

Web history (Wayback)

Domain	scpvitalife.com

Certificate / subdomain footprint

Subdomains	0